Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone

Renata Ferrarotto, Priyanka Pathak, Dipen Maheshbhai Maru, Atin Agarwal, Michael James Overman, Paulo M. Hoff, Edmund Scott Kopetz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has progressively increased over the past decades. Since the introduction of 5-fluorouracil (5-FU)-based chemotherapy, followed by hepatic resection of metastases, and more recently the adoption of newer chemotherapeutic regimens associated with targeted therapy, the gains are getting more substantial. Despite the recognition of the potential for long-term survival after surgical resection of metastatic disease, long-term survival data to determine the potential curative role of chemotherapy alone is lacking. Methods: We performed a retrospective review of 2751 patients who presented with mCRC at The MD Anderson Cancer Center from 1990 through 2003. Patients alive at 5 years who achieved complete response with chemotherapy and were not submitted to any surgical or interventional procedures directed to the metastatic sites were included in the analysis. Results: The 5-year overall survival rate for all patients with mCRC during this period was 10.8%. Among these long-term survivors, 2.2% achieved a sustained complete response after chemotherapy (all 6 with fluoropyrimidines and 2 with irinotecan) as the only treatment modality and were without evidence of disease until the last follow-up visit (median of 10.3 years). This number corresponds to 0.24% (6 of 2541) of all patients with mCRC included in this review. Conclusion: Cure with chemotherapy alone is possible for a very small number of patients with metastatic colorectal cancer. Improved therapies are increasing complete response rates, but the impact of modern chemotherapy on durable complete responses will require additional follow up.

Original languageEnglish (US)
Pages (from-to)178-182
Number of pages5
JournalClinical colorectal cancer
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2011

Fingerprint

Colorectal Neoplasms
Drug Therapy
irinotecan
Survival
Fluorouracil
Survivors
Therapeutics
Survival Rate
Neoplasm Metastasis
Liver
Neoplasms

Keywords

  • Cure with chemotherapy
  • Durable complete response
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. / Ferrarotto, Renata; Pathak, Priyanka; Maru, Dipen Maheshbhai; Agarwal, Atin; Overman, Michael James; Hoff, Paulo M.; Kopetz, Edmund Scott.

In: Clinical colorectal cancer, Vol. 10, No. 3, 01.01.2011, p. 178-182.

Research output: Contribution to journalArticle

@article{4bfde46bd375413f83c015ec2ed42438,
title = "Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone",
abstract = "Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has progressively increased over the past decades. Since the introduction of 5-fluorouracil (5-FU)-based chemotherapy, followed by hepatic resection of metastases, and more recently the adoption of newer chemotherapeutic regimens associated with targeted therapy, the gains are getting more substantial. Despite the recognition of the potential for long-term survival after surgical resection of metastatic disease, long-term survival data to determine the potential curative role of chemotherapy alone is lacking. Methods: We performed a retrospective review of 2751 patients who presented with mCRC at The MD Anderson Cancer Center from 1990 through 2003. Patients alive at 5 years who achieved complete response with chemotherapy and were not submitted to any surgical or interventional procedures directed to the metastatic sites were included in the analysis. Results: The 5-year overall survival rate for all patients with mCRC during this period was 10.8{\%}. Among these long-term survivors, 2.2{\%} achieved a sustained complete response after chemotherapy (all 6 with fluoropyrimidines and 2 with irinotecan) as the only treatment modality and were without evidence of disease until the last follow-up visit (median of 10.3 years). This number corresponds to 0.24{\%} (6 of 2541) of all patients with mCRC included in this review. Conclusion: Cure with chemotherapy alone is possible for a very small number of patients with metastatic colorectal cancer. Improved therapies are increasing complete response rates, but the impact of modern chemotherapy on durable complete responses will require additional follow up.",
keywords = "Cure with chemotherapy, Durable complete response, Metastatic colorectal cancer",
author = "Renata Ferrarotto and Priyanka Pathak and Maru, {Dipen Maheshbhai} and Atin Agarwal and Overman, {Michael James} and Hoff, {Paulo M.} and Kopetz, {Edmund Scott}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.clcc.2011.03.023",
language = "English (US)",
volume = "10",
pages = "178--182",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone

AU - Ferrarotto, Renata

AU - Pathak, Priyanka

AU - Maru, Dipen Maheshbhai

AU - Agarwal, Atin

AU - Overman, Michael James

AU - Hoff, Paulo M.

AU - Kopetz, Edmund Scott

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has progressively increased over the past decades. Since the introduction of 5-fluorouracil (5-FU)-based chemotherapy, followed by hepatic resection of metastases, and more recently the adoption of newer chemotherapeutic regimens associated with targeted therapy, the gains are getting more substantial. Despite the recognition of the potential for long-term survival after surgical resection of metastatic disease, long-term survival data to determine the potential curative role of chemotherapy alone is lacking. Methods: We performed a retrospective review of 2751 patients who presented with mCRC at The MD Anderson Cancer Center from 1990 through 2003. Patients alive at 5 years who achieved complete response with chemotherapy and were not submitted to any surgical or interventional procedures directed to the metastatic sites were included in the analysis. Results: The 5-year overall survival rate for all patients with mCRC during this period was 10.8%. Among these long-term survivors, 2.2% achieved a sustained complete response after chemotherapy (all 6 with fluoropyrimidines and 2 with irinotecan) as the only treatment modality and were without evidence of disease until the last follow-up visit (median of 10.3 years). This number corresponds to 0.24% (6 of 2541) of all patients with mCRC included in this review. Conclusion: Cure with chemotherapy alone is possible for a very small number of patients with metastatic colorectal cancer. Improved therapies are increasing complete response rates, but the impact of modern chemotherapy on durable complete responses will require additional follow up.

AB - Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has progressively increased over the past decades. Since the introduction of 5-fluorouracil (5-FU)-based chemotherapy, followed by hepatic resection of metastases, and more recently the adoption of newer chemotherapeutic regimens associated with targeted therapy, the gains are getting more substantial. Despite the recognition of the potential for long-term survival after surgical resection of metastatic disease, long-term survival data to determine the potential curative role of chemotherapy alone is lacking. Methods: We performed a retrospective review of 2751 patients who presented with mCRC at The MD Anderson Cancer Center from 1990 through 2003. Patients alive at 5 years who achieved complete response with chemotherapy and were not submitted to any surgical or interventional procedures directed to the metastatic sites were included in the analysis. Results: The 5-year overall survival rate for all patients with mCRC during this period was 10.8%. Among these long-term survivors, 2.2% achieved a sustained complete response after chemotherapy (all 6 with fluoropyrimidines and 2 with irinotecan) as the only treatment modality and were without evidence of disease until the last follow-up visit (median of 10.3 years). This number corresponds to 0.24% (6 of 2541) of all patients with mCRC included in this review. Conclusion: Cure with chemotherapy alone is possible for a very small number of patients with metastatic colorectal cancer. Improved therapies are increasing complete response rates, but the impact of modern chemotherapy on durable complete responses will require additional follow up.

KW - Cure with chemotherapy

KW - Durable complete response

KW - Metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=80052511917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052511917&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2011.03.023

DO - 10.1016/j.clcc.2011.03.023

M3 - Article

C2 - 21855039

AN - SCOPUS:80052511917

VL - 10

SP - 178

EP - 182

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 3

ER -